



Novel and Improved Strategies for the Detection, Diagnosis and Treatment of Biofilm-Associated Infections

Guest Editors:

Dr. Celia Mayer

Escherichia coli Reference
Laboratory (LREC)-Fundación
Instituto de Investigación
Sanitaria Santiago de
Compostela (FIDIS), 15706
Santiago de Compostela, Spain

**Dr. Saskia Camille Flament
Simon**

Escherichia coli reference
laboratory (LREC), Facultade de
Veterinaria, Universidade de
Santiago de Compostela, 27002
Lugo, Spain

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Several microorganisms are difficult to eradicate due to their ability to produce biofilm on several kinds of surfaces, protecting themselves from a wide range of antimicrobials. The diagnosis of clinically relevant biofilm infections is often difficult and inconsistent, as well as there are controversies and uncertainties concerning treatment or prophylactic approaches using antibiotics in clinical settings. Furthermore, conventional antibiotic therapies used to treat acute infections may not eliminate chronic biofilm infections and, in many cases, promote resistance and further biofilm formation. Therefore, the successful treatment of biofilm-associated infections requires novel and more effective anti-biofilm strategies. More targeted therapeutics for biofilm are also required for selecting the appropriate and specific treatment to achieve clinical efficacy. Aware of these facts, the main subject of this Special Issue includes any novel and new diagnostic tool to identify biofilms in infections and improved anti-biofilm strategies and therapies that could be used to control and treat relevant biofilm-based infections.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)